Login Register Cart 0
Review Article

二肽基肽酶IV抑制剂开发的最新药物化学方法

卷 28, 期 18, 2021

发表于: 12 October, 2020

页: [3595 - 3621] 页: 27

弟呕挨: 10.2174/0929867327666201012153255

价格: $65

摘要

背景：糖尿病是一种代谢性疾病，因胰岛素降低或不影响血糖水平而发生。目前口服药物刺激胰岛素释放，增加葡萄糖吸收和利用，降低肝脏葡萄糖输出。两种主要肠促胰岛素激素如葡萄糖依赖的促胰岛素多肽(GIP)和胰高血糖素样肽-1 (GLP-1)刺激饭后胰岛素的释放，但它们的作用被二肽基肽酶- IV所抑制。 目的：内源性GLP-1和GIP的活性随着DPP IV抑制剂的增加而延长，DPP IV抑制剂负责刺激胰岛素分泌和调节血糖水平。DPP IV抑制剂已显示出有效性和耐受性，在2型糖尿病的管理中，对体重的中性影响以及低血糖的机会更少。这些旅程从Sitagliptin(2006年上市)开始，到Evogliptin(2015年上市，韩国)。 结论：2型糖尿病的治疗包括生活方式的改变，口服药物和胰岛素。与目前的处方药相比，更需要更新和更优越的疗法。人们已经尝试了各种杂环衍生物，但由于对DASH蛋白、CYP酶和hERG通道的掩盖，它们显示出了副作用。在此基础上，研究的重点是开发安全、有影响、选择性和长效的DPP IV抑制剂。

关键词: 糖尿病，DPP IV抑制剂，GLP -1，杂环衍生物，2型糖尿病，CYP酶

« Previous Next »
[1]
IDF DIABETES ATLAS. 9th edition 2019. Available at: https://www.diabetesatlas.org/en/ (accessed on Dec 12th, 2018).
[2]
Kaveeshwar, S.A.; Cornwall, J. The current state of diabetes mellitus in India. Australas. Med. J., 2014, 7(1), 45-48.
[http://dx.doi.org/10.4066/AMJ.2014.1979] [PMID: 24567766]
[3]
Zheng, Y.; Ley, S.H.; Hu, F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol., 2018, 14(2), 88-98.
[http://dx.doi.org/10.1038/nrendo.2017.151] [PMID: 29219149]
[4]
Pathak, R.; Bridgeman, M.B. Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes. P&T, 2010, 35(9), 509-513.
[PMID: 20975810]
[5]
Neumiller, J.J. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003), 2009, 49((Suppl. 1)), S16-S29.
[http://dx.doi.org/10.1331/JAPhA.2009.09078] [PMID: 19801361]
[6]
Nathan, D.M.; Buse, J.B.; Davidson, M.B.; Heine, R.J.; Holman, R.R.; Sherwin, R.; Zinman, B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes association and the European association for the study of diabetes. Diabetes Care, 2006, 29(8), 1963-1972.
[http://dx.doi.org/10.2337/dc06-9912] [PMID: 16873813]
[7]
Barnett, A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int. J. Clin. Pract., 2006, 60(11), 1454-1470.
[http://dx.doi.org/10.1111/j.1742-1241.2006.01178.x] [PMID: 17073841]
[8]
Sebokova, E.; Christ, A.D.; Boehringer, M.; Mizrahi, J. Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes. Curr. Top. Med. Chem., 2007, 7(6), 547-555.
[http://dx.doi.org/10.2174/156802607780091019] [PMID: 17352676]
[9]
Green, B.D.; Flatt, P.R.; Bailey, C.J. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab. Vasc. Dis. Res., 2006, 3(3), 159-165.
[http://dx.doi.org/10.3132/dvdr.2006.024] [PMID: 17160910]
[10]
Hopsu-Havu, V.K.; Glenner, G.G. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide. Histochemie, 1966, 7(3), 197-201.
[http://dx.doi.org/10.1007/BF00577838] [PMID: 5959122]
[11]
Wagner, L.; Klemann, C.; Stephan, M.; von Hörsten, S. Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins. Clin. Exp. Immunol., 2016, 184(3), 265-283.
[http://dx.doi.org/10.1111/cei.12757] [PMID: 26671446]
[12]
Omar, B.A.; Liehua, L.; Yamada, Y.; Seino, Y.; Marchetti, P.; Ahrén, B. Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia, 2014, 57(9), 1876-1883.
[http://dx.doi.org/10.1007/s00125-014-3299-4] [PMID: 24939431]
[13]
Mulvihill, E.E.; Drucker, D.J. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr. Rev., 2014, 35(6), 992-1019.
[http://dx.doi.org/10.1210/er.2014-1035] [PMID: 25216328]
[14]
Thomas, L.; Eckhardt, M.; Langkopf, E.; Tadayyon, M.; Himmelsbach, F.; Mark, M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J. Pharmacol. Exp. Ther., 2008, 325(1), 175-182.
[http://dx.doi.org/10.1124/jpet.107.135723] [PMID: 18223196]
[15]
Deacon, C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes. Metab., 2011, 13(1), 7-18.
[http://dx.doi.org/10.1111/j.1463-1326.2010.01306.x] [PMID: 21114598]
[16]
DiaTribe Learn, making sense of diabetes. DPP-4 inhibitors. Available at: https://diatribe.org/dpp-4-inhibitors (accessed on Januray 12th, 2019).
[17]
Haffner, C.D.; McDougald, D.L.; Reister, S.M.; Thompson, B.D.; Conlee, C.; Fang, J.; Bass, J.; Lenhard, J.M.; Croom, D.; Secosky-Chang, M.B.; Tomaszek, T.; McConn, D.; Wells-Knecht, K.; Johnson, P.R. 2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV. Bioorg. Med. Chem. Lett., 2005, 15(23), 5257-5261.
[http://dx.doi.org/10.1016/j.bmcl.2005.08.050] [PMID: 16168640]
[18]
Sakashita, H.; Kitajima, H.; Nakamura, M.; Akahoshi, F.; Hayashi, Y. 1-((S)-γ-substituted prolyl)-(S)-2-cyanopyrro-lidine as a novel series of highly potent DPP-IV inhibitors. Bioorg. Med. Chem. Lett., 2005, 15(10), 2441-2445.
[http://dx.doi.org/10.1016/j.bmcl.2005.03.077] [PMID: 15863294]
[19]
Wright, S.W.; Ammirati, M.J.; Andrews, K.M.; Brodeur, A.M.; Danley, D.E.; Doran, S.D.; Lillquist, J.S.; McClure, L.D.; McPherson, R.K.; Orena, S.J.; Parker, J.C.; Polivkova, J.; Qiu, X.; Soeller, W.C.; Soglia, C.B.; Treadway, J.L.; VanVolkenburg, M.A.; Wang, H.; Wilder, D.C.; Olson, T.V. Cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization. J. Med. Chem., 2006, 49(11), 3068-3076.
[http://dx.doi.org/10.1021/jm0600085] [PMID: 16722626]
[20]
Coumar, M.S.; Chang, C.N.; Chen, C.T.; Chen, X.; Chien, C.H.; Tsai, T.Y.; Cheng, J.H.; Wu, H.Y.; Han, C.H.; Wu, S.H.; Huang, Y.W.; Hsu, T.; Hsu, L.J.; Chao, Y.S.; Hsieh, H.P.; Jiaang, W.T. 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes. Bioorg. Med. Chem. Lett., 2007, 17(5), 1274-1279.
[http://dx.doi.org/10.1016/j.bmcl.2006.12.019] [PMID: 17194587]
[21]
Corbett, J.W.; Dirico, K.; Song, W.; Boscoe, B.P.; Doran, S.D.; Boyer, D.; Qiu, X.; Ammirati, M.; Vanvolkenburg, M.A.; McPherson, R.K.; Parker, J.C.; Cox, E.D. Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(24), 6707-6713.
[http://dx.doi.org/10.1016/j.bmcl.2007.10.063] [PMID: 17977724]
[22]
Fukushima, H.; Hiratate, A.; Takahashi, M.; Mikami, A.; Saito-Hori, M.; Munetomo, E.; Kitano, K.; Chonan, S.; Saito, H.; Suzuki, A.; Takaoka, Y.; Yamamoto, K. Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem., 2008, 16(7), 4093-4106.
[http://dx.doi.org/10.1016/j.bmc.2008.01.016] [PMID: 18243000]
[23]
Kato, N.; Oka, M.; Murase, T.; Yoshida, M.; Sakairi, M.; Yamashita, S.; Yasuda, Y.; Yoshikawa, A.; Hayashi, Y.; Makino, M.; Takeda, M. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl} amino)-2-methylpropyl]-2-methylpyrazolo [1, 5-a] pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg. Med. Chem., 2011, 19(23), 7221-7227.
[http://dx.doi.org/10.1016/j.bmc.2011.09.043] [PMID: 22019046]
[24]
Zhao, G.; Kwon, C.; Wang, A.; Robertson, J.G.; Marcinkeviciene, J.; Parker, R.A.; Kirby, M.S.; Hamann, L.G. Substituted piperidinyl glycinyl 2-cyano-4,5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2013, 23(6), 1622-1625.
[http://dx.doi.org/10.1016/j.bmcl.2013.01.104] [PMID: 23416006]
[25]
Kuranov, S.O.; Tsypysheva, I.P.; Khvostov, M.V.; Zainullina, L.F.; Borisevich, S.S.; Vakhitova, Y.V.; Luzina, O.A.; Salakhutdinov, N.F. Synthesis and evaluation of camphor and cytisine-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus. Bioorg. Med. Chem., 2018, 26(15), 4402-4409.
[http://dx.doi.org/10.1016/j.bmc.2018.07.018] [PMID: 30056037]
[26]
Caldwell, C.G.; Chen, P.; He, J.; Parmee, E.R.; Leiting, B.; Marsilio, F.; Patel, R.A.; Wu, J.K.; Eiermann, G.J.; Petrov, A.; He, H.; Lyons, K.A.; Thornberry, N.A.; Weber, A.E. Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(5), 1265-1268.
[http://dx.doi.org/10.1016/j.bmcl.2003.12.040] [PMID: 14980678]
[27]
Hulin, B.; Cabral, S.; Lopaze, M.G.; Van Volkenburg, M.A.; Andrews, K.M.; Parker, J.C. New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2005, 15(21), 4770-4773.
[http://dx.doi.org/10.1016/j.bmcl.2005.07.026] [PMID: 16115768]
[28]
Yeh, T.K.; Tsai, T.Y.; Hsu, T.; Cheng, J.H.; Chen, X.; Song, J.S.; Shy, H.S.; Chiou, M.C.; Chien, C.H.; Tseng, Y.J.; Huang, C.Y.; Yeh, K.C.; Huang, Y.L.; Huang, C.H.; Huang, Y.W.; Wang, M.H.; Tang, H.K.; Chao, Y.S.; Chen, C.T.; Jiaang, W.T. (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett., 2010, 20(12), 3596-3600.
[http://dx.doi.org/10.1016/j.bmcl.2010.04.124] [PMID: 20483603]
[29]
Tajima, A.; Yamamoto, K.; Kozakai, A.; Okumura-Kitajima, L.; Mita, Y.; Kitano, K.; Jingu, S.; Nakaike, S. (2S,4S)-4-Fluoro-1-[(2-hydroxy-1,1-dimethylethyl)amino]acetyl-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor. Eur. J. Pharmacol., 2011, 655(1-3), 99-107.
[http://dx.doi.org/10.1016/j.ejphar.2011.01.010] [PMID: 21262219]
[30]
Sharma, M.; Gupta, M.; Singh, D.; Kumar, M.; Kaur, P. Synthesis, evaluation and molecular docking of prolyl-fluoropyrrolidine derivatives as dipeptidyl peptidase IV inhibitors. Chem. Biol. Drug Des., 2013, 82(2), 156-166.
[http://dx.doi.org/10.1111/cbdd.12142] [PMID: 23581745]
[31]
Ferraris, D.; Ko, Y.S.; Calvin, D.; Chiou, T.; Lautar, S.; Thomas, B.; Wozniak, K.; Rojas, C.; Kalish, V.; Belyakov, S. Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(22), 5579-5583.
[http://dx.doi.org/10.1016/j.bmcl.2004.08.057] [PMID: 15482928]
[32]
Zhao, K.; Lim, D.S.; Funaki, T.; Welch, J.T. Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoro-propylidene)-cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic. Bioorg. Med. Chem., 2003, 11(2), 207-215.
[http://dx.doi.org/10.1016/S0968-0896(02)00384-X] [PMID: 12470715]
[33]
Van der Veken, P.; Senten, K.; Kertèsz, I.; De Meester, I.; Lambeir, A.M.; Maes, M.B.; Scharpé, S.; Haemers, A.; Augustyns, K. Fluoro-olefins as peptidomimetic inhibitors of dipeptidyl peptidases. J. Med. Chem., 2005, 48(6), 1768-1780.
[http://dx.doi.org/10.1021/jm0495982] [PMID: 15771423]
[34]
Edmondson, S.D.; Wei, L.; Xu, J.; Shang, J.; Xu, S.; Pang, J.; Chaudhary, A.; Dean, D.C.; He, H.; Leiting, B.; Lyons, K.A.; Patel, R.A.; Patel, S.B.; Scapin, G.; Wu, J.K.; Beconi, M.G.; Thornberry, N.A.; Weber, A.E. Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(7), 2409-2413.
[http://dx.doi.org/10.1016/j.bmcl.2008.02.050] [PMID: 18331795]
[35]
Edmondson, S.D.; Mastracchio, A.; Beconi, M.; Colwell, L.F., Jr; Habulihaz, B.; He, H.; Kumar, S.; Leiting, B.; Lyons, K.A.; Mao, A.; Marsilio, F.; Patel, R.A.; Wu, J.K.; Zhu, L.; Thornberry, N.A.; Weber, A.E.; Parmee, E.R. Potent and selective proline derived dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(20), 5151-5155.
[http://dx.doi.org/10.1016/j.bmcl.2004.07.056] [PMID: 15380217]
[36]
Backes, B.J.; Longenecker, K.; Hamilton, G.L.; Stewart, K.; Lai, C.; Kopecka, H.; von Geldern, T.W.; Madar, D.J.; Pei, Z.; Lubben, T.H.; Zinker, B.A.; Tian, Z.; Ballaron, S.J.; Stashko, M.A.; Mika, A.K.; Beno, D.W.; Kempf-Grote, A.J.; Black-Schaefer, C.; Sham, H.L.; Trevillyan, J.M. Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit. Bioorg. Med. Chem. Lett., 2007, 17(7), 2005-2012.
[http://dx.doi.org/10.1016/j.bmcl.2007.01.026] [PMID: 17276063]
[37]
Kondo, T.; Nekado, T.; Sugimoto, I.; Ochi, K.; Takai, S.; Kinoshita, A.; Hatayama, A.; Yamamoto, S.; Kishikawa, K.; Nakai, H.; Toda, M. Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group. Bioorg. Med. Chem., 2008, 16(4), 1613-1631.
[http://dx.doi.org/10.1016/j.bmc.2007.11.031] [PMID: 18039579]
[38]
Andrews, K.M.; Beebe, D.A.; Benbow, J.W.; Boyer, D.A.; Doran, S.D.; Hui, Y.; Liu, S.; McPherson, R.K.; Neagu, C.; Parker, J.C.; Piotrowski, D.W.; Schneider, S.R.; Treadway, J.L.; VanVolkenberg, M.A.; Zembrowski, W.J. 1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett., 2011, 21(6), 1810-1814.
[http://dx.doi.org/10.1016/j.bmcl.2011.01.055] [PMID: 21324688]
[39]
Jiang, T.; Zhou, Y.; Zhu, J.; Chen, Z.; Sun, P.; Zhang, Q.; Wang, Z.; Shao, Q.; Jiang, X.; Li, B.; Wang, H.; Zhu, W.; Shen, J. Design, synthesis, and pharmacological evaluation of highly potent and selective dipeptidyl peptidase-4 inhibitors. Arch. Pharm. (Weinheim), 2015, 348(6), 399-407.
[http://dx.doi.org/10.1002/ardp.201500082] [PMID: 25871012]
[40]
Cox, J.M.; Chu, H.D.; Kuethe, J.T.; Gao, Y.D.; Scapin, G.; Eiermann, G.; He, H.; Li, X.; Lyons, K.A.; Metzger, J.; Petrov, A.; Wu, J.K.; Xu, S.; Sinha-Roy, R.; Weber, A.E.; Biftu, T. The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors. Bioorg. Med. Chem. Lett., 2016, 26(11), 2622-2626.
[http://dx.doi.org/10.1016/j.bmcl.2016.04.020] [PMID: 27106708]
[41]
Wu, D.; Jin, F.; Lu, W.; Zhu, J.; Li, C.; Wang, W.; Tang, Y.; Jiang, H.; Huang, J.; Liu, G.; Li, J. Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors. Chem. Biol. Drug Des., 2012, 79(6), 897-906.
[http://dx.doi.org/10.1111/j.1747-0285.2012.01365.x] [PMID: 22381062]
[42]
Sagar, S.R.; Agarwal, J.K.; Pandya, D.H.; Dash, R.P.; Nivsarkar, M.; Vasu, K.K. Design, synthesis and biological evaluation of novel pyrazolo-pyrimidinones as DPP-IV inhibitors in diabetes. Bioorg. Med. Chem. Lett., 2015, 25(20), 4428-4433.
[http://dx.doi.org/10.1016/j.bmcl.2015.09.015] [PMID: 26372650]
[43]
Villhauer, E.B.; Novartis, A.G.N.N. N-(Substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containingthem and their use in inhibiting dipeptidyl peptidase-IV. US Patent 6,110,949, 29 August;2000
[44]
Park, W.S.; Kang, S.K.; Jun, M.A.; Shin, M.S.; Kim, K.Y.; Rhee, S.D.; Bae, M.A.; Kim, M.S.; Kim, K.R.; Kang, N.S.; Yoo, S.E.; Lee, J.O.; Song, D.H.; Silinski, P.; Schneider, S.E.; Ahn, J.H.; Kim, S.S. Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(5), 1366-1370.
[http://dx.doi.org/10.1016/j.bmcl.2011.01.041] [PMID: 21306895]
[45]
Yoshida, T.; Akahoshi, F.; Sakashita, H.; Kitajima, H.; Nakamura, M.; Sonda, S.; Takeuchi, M.; Tanaka, Y.; Ueda, N.; Sekiguchi, S.; Ishige, T.; Shima, K.; Nabeno, M.; Abe, Y.; Anabuki, J.; Soejima, A.; Yoshida, K.; Takashina, Y.; Ishii, S.; Kiuchi, S.; Fukuda, S.; Tsutsumiuchi, R.; Kosaka, K.; Murozono, T.; Nakamaru, Y.; Utsumi, H.; Masutomi, N.; Kishida, H.; Miyaguchi, I.; Hayashi, Y. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem., 2012, 20(19), 5705-5719.
[http://dx.doi.org/10.1016/j.bmc.2012.08.012] [PMID: 22959556]
[46]
Yoshida, T.; Akahoshi, F.; Sakashita, H.; Sonda, S.; Takeuchi, M.; Tanaka, Y.; Nabeno, M.; Kishida, H.; Miyaguchi, I.; Hayashi, Y. Fused bicyclic heteroarylpiperazine-substituted L-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group. Bioorg. Med. Chem., 2012, 20(16), 5033-5041.
[http://dx.doi.org/10.1016/j.bmc.2012.06.033] [PMID: 22824762]
[47]
Xu, J.; Ok, H.O.; Gonzalez, E.J.; Colwell, L.F., Jr; Habulihaz, B.; He, H.; Leiting, B.; Lyons, K.A.; Marsilio, F.; Patel, R.A.; Wu, J.K.; Thornberry, N.A.; Weber, A.E.; Parmee, E.R. Discovery of potent and selective β-homophenylalanine based dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(18), 4759-4762.
[http://dx.doi.org/10.1016/j.bmcl.2004.06.099] [PMID: 15324903]
[48]
Nitta, A.; Fujii, H.; Sakami, S.; Satoh, M.; Nakaki, J.; Satoh, S.; Kumagai, H.; Kawai, H. Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2012, 22(23), 7036-7040.
[http://dx.doi.org/10.1016/j.bmcl.2012.09.099] [PMID: 23072865]
[49]
Ali, Z.; Akhtar, M.J.; Siddiqui, A.A.; Khan, A.A.; Haider, M.R.; Yar, M.S. Design, synthesis, and biological evaluation of novel quinazoline clubbed thiazoline derivatives. Arch. Pharm. (Weinheim), 2017, 350(2), 1600298.
[http://dx.doi.org/10.1002/ardp.201600298] [PMID: 28093794]
[50]
Chen, P.; Caldwell, C.G.; Mathvink, R.J.; Leiting, B.; Marsilio, F.; Patel, R.A.; Wu, J.K.; He, H.; Lyons, K.A.; Thornberry, N.A.; Weber, A.E. Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes. Bioorg. Med. Chem. Lett., 2007, 17(21), 5853-5857.
[http://dx.doi.org/10.1016/j.bmcl.2007.08.030] [PMID: 17869513]
[51]
Wallace, M.B.; Feng, J.; Zhang, Z.; Skene, R.J.; Shi, L.; Caster, C.L.; Kassel, D.B.; Xu, R.; Gwaltney, S.L. II. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(7), 2362-2367.
[http://dx.doi.org/10.1016/j.bmcl.2008.02.071] [PMID: 18346892]
[52]
Wang, L.; Zhang, B.; Ji, J.; Li, B.; Yan, J.; Zhang, W.; Wu, Y.; Wang, X. Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors. Eur. J. Med. Chem., 2009, 44(8), 3318-3322.
[http://dx.doi.org/10.1016/j.ejmech.2009.03.021] [PMID: 19375196]
[53]
O’Connor, S.P.; Wang, Y.; Simpkins, L.M.; Brigance, R.P.; Meng, W.; Wang, A.; Kirby, M.S.; Weigelt, C.A.; Hamann, L.G. Synthesis, SAR, and atropisomerism of imidazolopyrimidine DPP4 inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(21), 6273-6276.
[http://dx.doi.org/10.1016/j.bmcl.2010.08.090] [PMID: 20833042]
[54]
Ikuma, Y.; Hochigai, H.; Kimura, H.; Nunami, N.; Kobayashi, T.; Uchiyama, K.; Furuta, Y.; Sakai, M.; Horiguchi, M.; Masui, Y.; Okazaki, K.; Sato, Y.; Nakahira, H. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors. Bioorg. Med. Chem., 2012, 20(19), 5864-5883.
[http://dx.doi.org/10.1016/j.bmc.2012.07.046] [PMID: 22938786]
[55]
Li, Q.; Zhou, M.; Han, L.; Cao, Q.; Wang, X.; Zhao, L.; Zhou, J.; Zhang, H. Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors. Chem. Biol. Drug Des., 2015, 86(4), 849-856.
[http://dx.doi.org/10.1111/cbdd.12560] [PMID: 25787859]
[56]
Karandikar, S.; Soni, R.; Soman, S.S.; Umar, S.; Suresh, B. 1, 2-Benzisoxazole-3-acetamide derivatives as dual agents for DPP-IV inhibition and anticancer activity. Synth. Commun., 2018, 48(22), 2877-2887.
[http://dx.doi.org/10.1080/00397911.2018.1508723]
[57]
Gao, Y.D.; Feng, D.; Sheridan, R.P.; Scapin, G.; Patel, S.B.; Wu, J.K.; Zhang, X.; Sinha-Roy, R.; Thornberry, N.A.; Weber, A.E.; Biftu, T. Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(14), 3877-3879.
[http://dx.doi.org/10.1016/j.bmcl.2007.04.106] [PMID: 17502141]
[58]
Wang, W.; Devasthale, P.; Wang, A.; Harrity, T.; Egan, D.; Morgan, N.; Cap, M.; Fura, A.; Klei, H.E.; Kish, K.; Weigelt, C.; Sun, L.; Levesque, P.; Li, Y.X.; Zahler, R.; Kirby, M.S.; Hamann, L.G. 7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site. Bioorg. Med. Chem. Lett., 2011, 21(22), 6646-6651.
[http://dx.doi.org/10.1016/j.bmcl.2011.09.074] [PMID: 21996520]
[59]
Xie, H.; Zeng, L.; Zeng, S.; Lu, X.; Zhang, G.; Zhao, X.; Cheng, N.; Tu, Z.; Li, Z.; Xu, H.; Yang, L.; Zhang, X.; Huang, M.; Zhao, J.; Hu, W. Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization. Eur. J. Med. Chem., 2012, 52, 205-212.
[http://dx.doi.org/10.1016/j.ejmech.2012.03.015] [PMID: 22475866]
[60]
Kim, D.; Wang, L.; Beconi, M.; Eiermann, G.J.; Fisher, M.H.; He, H.; Hickey, G.J.; Kowalchick, J.E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M.E.; Patel, R.A.; Petrov, A.; Scapin, G.; Patel, S.B.; Roy, R.S.; Wu, J.K.; Wyvratt, M.J.; Zhang, B.B.; Zhu, L.; Thornberry, N.A.; Weber, A.E. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4] triazolo [4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2005, 48(1), 141-151.
[http://dx.doi.org/10.1021/jm0493156] [PMID: 15634008]
[61]
Kowalchick, J.E.; Leiting, B.; Pryor, K.D.; Marsilio, F.; Wu, J.K.; He, H.; Lyons, K.A.; Eiermann, G.J.; Petrov, A.; Scapin, G.; Patel, R.A.; Thornberry, N.A.; Weber, A.E.; Kim, D. Design, synthesis, and biological evaluation of triazolopiperazine-based β-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(21), 5934-5939.
[http://dx.doi.org/10.1016/j.bmcl.2007.07.100] [PMID: 17827003]
[62]
Sharma, M.; Gupta, M.; Singh, D.; Kumar, M.; Kaur, P. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors. Chem. Biol. Drug Des., 2012, 80(6), 918-928.
[http://dx.doi.org/10.1111/cbdd.12041] [PMID: 22943413]
[63]
Gomha, S.M.; Eldebss, T.M.; Badrey, M.G.; Abdulla, M.M.; Mayhoub, A.S. Novel 4-heteroaryl-antipyrines as DPP-IV inhibitors. Chem. Biol. Drug Des., 2015, 86(5), 1292-1303.
[http://dx.doi.org/10.1111/cbdd.12593] [PMID: 26032047]
[64]
Schwehm, C.; Li, J.; Song, H.; Hu, X.; Kellam, B.; Stocks, M.J. Synthesis of new DPP-4 inhibitors based on a novel tricyclic scaffold. ACS Med. Chem. Lett., 2015, 6(3), 324-328.
[http://dx.doi.org/10.1021/ml500503n] [PMID: 25815154]
[65]
Deng, X.; Han, L.; Zhou, J.; Zhang, H.; Li, Q. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors. Bioorg. Chem., 2017, 75, 357-367.
[http://dx.doi.org/10.1016/j.bioorg.2017.10.010] [PMID: 29096096]
[66]
Li, Q.; Han, L.; Zhang, B.; Zhou, J.; Zhang, H. Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors. Org. Biomol. Chem., 2016, 14(40), 9598-9611.
[http://dx.doi.org/10.1039/C6OB01818A] [PMID: 27714283]
[67]
Zhang, Z.; Wallace, M.B.; Feng, J.; Stafford, J.A.; Skene, R.J.; Shi, L.; Lee, B.; Aertgeerts, K.; Jennings, A.; Xu, R.; Kassel, D.B.; Kaldor, S.W.; Navre, M.; Webb, D.R.; Gwaltney, S.L. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. J. Med. Chem., 2011, 54(2), 510-524.
[http://dx.doi.org/10.1021/jm101016w] [PMID: 21186796]
[68]
Meng, W.; Brigance, R.P.; Chao, H.J.; Fura, A.; Harrity, T.; Marcinkeviciene, J.; O’Connor, S.P.; Tamura, J.K.; Xie, D.; Zhang, Y.; Klei, H.E.; Kish, K.; Weigelt, C.A.; Turdi, H.; Wang, A.; Zahler, R.; Kirby, M.S.; Hamann, L.G. Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J. Med. Chem., 2010, 53(15), 5620-5628.
[http://dx.doi.org/10.1021/jm100634a] [PMID: 20684603]
[69]
Nishio, Y.; Kimura, H.; Sawada, N.; Sugaru, E.; Horiguchi, M.; Ono, M.; Furuta, Y.; Sakai, M.; Masui, Y.; Otani, M.; Hashizuka, T.; Honda, Y.; Deguchi, J.; Nakagawa, T.; Nakahira, H. 2-(6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-ylmethyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A. Bioorg. Med. Chem., 2011, 19(18), 5490-5499.
[http://dx.doi.org/10.1016/j.bmc.2011.07.042] [PMID: 21865048]
[70]
Deng, J.; Peng, L.; Zhang, G.; Lan, X.; Li, C.; Chen, F.; Zhou, Y.; Lin, Z.; Chen, L.; Dai, R.; Xu, H.; Yang, L.; Zhang, X.; Hu, W. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes. Eur. J. Med. Chem., 2011, 46(1), 71-76.
[http://dx.doi.org/10.1016/j.ejmech.2010.10.016] [PMID: 21106276]
[71]
Tomovic, K.; Ilic, B.S.; Miljkovic, M.; Dimov, S.; Yancheva, D.; Kojic, M.; Mavrova, A.T.; Kocic, G.; Smelcerovic, A. Benzo[4,5]thieno[2,3-d]pyrimidine phthalimide derivative, one of the rare noncompetitive inhibitors of dipeptidyl peptidase-4. Arch. Pharm. (Weinheim), 2020, 353(1), e1900238.
[http://dx.doi.org/10.1002/ardp.201900238] [PMID: 31710123]
[72]
Lai, Z.W.; Li, C.; Liu, J.; Kong, L.; Wen, X.; Sun, H. Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin. Eur. J. Med. Chem., 2014, 83, 547-560.
[http://dx.doi.org/10.1016/j.ejmech.2014.06.044] [PMID: 24996141]
[73]
Jha, V.; Bhadoriya, K.S. Synthesis, pharmacological evaluation and molecular docking studies of pyrimidinedione based DPP-4 inhibitors as antidiabetic agents. J. Mol. Struct., 2018, 1158, 96-105.
[http://dx.doi.org/10.1016/j.molstruc.2018.01.014]
[74]
Huang, J.; Deng, X.; Zhou, S.; Wang, N.; Qin, Y.; Meng, L.; Li, G.; Xiong, Y.; Fan, Y.; Guo, L.; Lan, D.; Xing, J.; Jiang, W.; Li, Q. Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent dipeptidyl peptidase-IV inhibitors. Bioorg. Med. Chem., 2019, 27(4), 644-654.
[http://dx.doi.org/10.1016/j.bmc.2019.01.001] [PMID: 30642693]
[75]
Miyamoto, Y.; Banno, Y.; Yamashita, T.; Fujimoto, T.; Oi, S.; Moritoh, Y.; Asakawa, T.; Kataoka, O.; Takeuchi, K.; Suzuki, N.; Ikedo, K.; Kosaka, T.; Tsubotani, S.; Tani, A.; Funami, M.; Amano, M.; Yamamoto, Y.; Aertgeerts, K.; Yano, J.; Maezaki, H. Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125. Bioorg. Med. Chem., 2011, 19(1), 172-185.
[http://dx.doi.org/10.1016/j.bmc.2010.11.038] [PMID: 21163664]
[76]
Kaczanowska, K.; Wiesmüller, K.H.; Schaffner, A.P. Design, synthesis, and in vitro evaluation of novel aminomethyl-pyridines as DPP-4 inhibitors. ACS Med. Chem. Lett., 2010, 1(9), 530-535.
[http://dx.doi.org/10.1021/ml100200c] [PMID: 24900243]
[77]
Peters, J.U.; Weber, S.; Kritter, S.; Weiss, P.; Wallier, A.; Zimmerli, D.; Boehringer, M.; Steger, M.; Loeffler, B.M. Aminomethylpyridines as DPP-IV inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(13), 3579-3580.
[http://dx.doi.org/10.1016/j.bmcl.2004.04.049] [PMID: 15177478]
[78]
Eckhardt, M.; Hauel, N.; Himmelsbach, F.; Langkopf, E.; Nar, H.; Mark, M.; Tadayyon, M.; Thomas, L.; Guth, B.; Lotz, R. 3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(11), 3158-3162.
[http://dx.doi.org/10.1016/j.bmcl.2008.04.075] [PMID: 18485703]
[79]
Namoto, K.; Sirockin, F.; Ostermann, N.; Gessier, F.; Flohr, S.; Sedrani, R.; Gerhartz, B.; Trappe, J.; Hassiepen, U.; Duttaroy, A.; Ferreira, S.; Sutton, J.M.; Clark, D.E.; Fenton, G.; Beswick, M.; Baeschlin, D.K. Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett., 2014, 24(3), 731-736.
[http://dx.doi.org/10.1016/j.bmcl.2013.12.118] [PMID: 24439847]
[80]
Kim, H.J.; Kwak, W.Y.; Min, J.P.; Lee, J.Y.; Yoon, T.H.; Kim, H.D.; Shin, C.Y.; Kim, M.K.; Choi, S.H.; Kim, H.S.; Yang, E.K.; Cheong, Y.H.; Chae, Y.N.; Park, K.J.; Jang, J.M.; Choi, S.J.; Son, M.H.; Kim, S.H.; Yoo, M.; Lee, B.J. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett., 2011, 21(12), 3809-3812.
[http://dx.doi.org/10.1016/j.bmcl.2011.04.029] [PMID: 21570283]
[81]
Kushwaha, R.N.; Srivastava, R.; Mishra, A.; Rawat, A.K.; Srivastava, A.K.; Haq, W.; Katti, S.B. Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes. Chem. Biol. Drug Des., 2015, 85(4), 439-446.
[http://dx.doi.org/10.1111/cbdd.12426] [PMID: 25216392]
[82]
Edmondson, S.D.; Mastracchio, A.; Cox, J.M.; Eiermann, G.J.; He, H.; Lyons, K.A.; Patel, R.A.; Patel, S.B.; Petrov, A.; Scapin, G.; Wu, J.K.; Xu, S.; Zhu, B.; Thornberry, N.A.; Roy, R.S.; Weber, A.E. Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(15), 4097-4101.
[http://dx.doi.org/10.1016/j.bmcl.2009.06.011] [PMID: 19539471]
[83]
Gupta, R.C.; Chhipa, L.; Mandhare, A.B.; Zambad, S.P.; Chauthaiwale, V.; Nadkarni, S.S.; Dutt, C. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor. Bioorg. Med. Chem. Lett., 2009, 19(17), 5021-5025.
[http://dx.doi.org/10.1016/j.bmcl.2009.07.058] [PMID: 19643608]
[84]
Benbow, J.W.; Andrews, K.A.; Aubrecht, J.; Beebe, D.; Boyer, D.; Doran, S.; Homiski, M.; Hui, Y.; McPherson, K.; Parker, J.C.; Treadway, J.; Vanvolkenberg, M.; Zembrowski, W.J. Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett., 2009, 19(8), 2220-2223.
[http://dx.doi.org/10.1016/j.bmcl.2009.02.099] [PMID: 19285862]
[85]
Nishio, Y.; Kimura, H.; Tosaki, S.; Sugaru, E.; Sakai, M.; Horiguchi, M.; Masui, Y.; Ono, M.; Nakagawa, T.; Nakahira, H. Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore. Bioorg. Med. Chem. Lett., 2010, 20(24), 7246-7249.
[http://dx.doi.org/10.1016/j.bmcl.2010.10.101] [PMID: 21074430]
[86]
Chen, P.; Caldwell, C.G.; Ashton, W.; Wu, J.K.; He, H.; Lyons, K.A.; Thornberry, N.A.; Weber, A.E. Synthesis and evaluation of [(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]cyclohexanes and 4-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(6), 1880-1886.
[http://dx.doi.org/10.1016/j.bmcl.2010.12.060] [PMID: 21320777]
[87]
Xing, J.; Li, Q.; Zhang, S.; Liu, H.; Zhao, L.; Cheng, H.; Zhang, Y.; Zhou, J.; Zhang, H. Identification of dipeptidyl peptidase IV inhibitors: virtual screening, synthesis and biological evaluation. Chem. Biol. Drug Des., 2014, 84(3), 364-377.
[http://dx.doi.org/10.1111/cbdd.12327] [PMID: 24674599]
[88]
Jadav, P.; Bahekar, R.; Shah, S.R.; Patel, D.; Joharapurkar, A.; Jain, M.; Sairam, K.V.; Singh, P.K. Design, synthesis and biological evaluation of novel aminomethyl-piperidones based DPP-IV inhibitors. Bioorg. Med. Chem. Lett., 2014, 24(8), 1918-1922.
[http://dx.doi.org/10.1016/j.bmcl.2014.03.009] [PMID: 24675378]
[89]
Ran, Y.; Pei, H.; Shao, M.; Chen, L. Synthesis, biological evaluation, and molecular docking of (R)-2-((8-(3-aminopiperidin-1-yl)-3-methyl-7-(3-methylbut-2-en-1-yl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)methyl)benzonitrile as dipeptidyl peptidase IV inhibitors. Chem. Biol. Drug Des., 2016, 87(2), 290-295.
[http://dx.doi.org/10.1111/cbdd.12663] [PMID: 26426933]
[90]
Srivastava, J.K.; Dubey, P.; Singh, S.; Bhat, H.R.; Kumawat, M.K.; Singh, U.P. Discovery of novel 1, 3, 5-triazine-thiazolidine-2, 4-diones as dipeptidyl peptidase-4 inhibitors with antibacterial activity targeting the S1 pocket for the treatment of type 2 diabetes. RSC Advances, 2015, 5(19), 14095-14102.
[http://dx.doi.org/10.1039/C4RA16903D ]
[91]
Wang, Y.; Tang, X.; Yi, L. Design and discovery of novel 1,3,5-triazines as dipeptidyl peptidase-4 inhibitor against diabetes. Pharmacology, 2019, 103(5-6), 273-281.
[http://dx.doi.org/10.1159/000494060] [PMID: 30799431]
[92]
Patel, B.D.; Bhadada, S.V.; Ghate, M.D. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors. Bioorg. Chem., 2017, 72, 345-358.
[http://dx.doi.org/10.1016/j.bioorg.2017.03.004] [PMID: 28302310]
[93]
Ahn, J.H.; Shin, M.S.; Jun, M.A.; Jung, S.H.; Kang, S.K.; Kim, K.R.; Rhee, S.D.; Kang, N.S.; Kim, S.Y.; Sohn, S.K.; Kim, S.G.; Jin, M.S.; Lee, J.O.; Cheon, H.G.; Kim, S.S. Synthesis, biological evaluation and structural determination of β-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(9), 2622-2628.
[http://dx.doi.org/10.1016/j.bmcl.2007.01.111] [PMID: 17331715]
[94]
Biftu, T.; Qian, X.; Chen, P.; Feng, D.; Scapin, G.; Gao, Y.D.; Cox, J.; Roy, R.S.; Eiermann, G.; He, H.; Lyons, K. Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: profile of clinical candidate (2R, 3S, 5R)-2-(2, 5-difluorophenyl)-5-[2-(methylsulfonyl)-2, 6-dihydropyrrolo [3, 4-c] pyrazol-5 (4H)-yl] tetrahydro-2H-pyran-3-amine (23). Bioorg. Med. Chem. Lett., 2013, 23(19), 5361-5366.
[http://dx.doi.org/10.1016/j.bmcl.2013.07.061] [PMID: 23972441]
[95]
Han, B.; Liu, J.L.; Huan, Y.; Li, P.; Wu, Q.; Lin, Z.Y.; Shen, Z.F.; Huang, H.H. Design, synthesis and primary activity of thiomorpholine derivatives as DPP-IV inhibitors. Chin. Chem. Lett., 2012, 23(3), 297-300.
[http://dx.doi.org/10.1016/j.cclet.2011.12.007 ]
[96]
Jiaang, W.T.; Chen, Y.S.; Hsu, T.; Wu, S.H.; Chien, C.H.; Chang, C.N.; Chang, S.P.; Lee, S.J.; Chen, X. Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg. Med. Chem. Lett., 2005, 15(3), 687-691.
[http://dx.doi.org/10.1016/j.bmcl.2004.11.023] [PMID: 15664838]
[97]
Kato, N.; Oka, M.; Murase, T.; Yoshida, M.; Sakairi, M.; Yakufu, M.; Yamashita, S.; Yasuda, Y.; Yoshikawa, A.; Hayashi, Y.; Shirai, M.; Mizuno, Y.; Takeuchi, M.; Makino, M.; Takeda, M.; Kakigami, T. Synthesis and pharmacological characterization of potent, selective, and orally bioavailable isoindoline class dipeptidyl peptidase IV inhibitors. Org. Med. Chem. Lett., 2011, 1(1), 7.
[http://dx.doi.org/10.1186/2191-2858-1-7] [PMID: 22373386]
[98]
Xiao, P.F.; Guo, R.; Huang, S.Q.; Cui, H.J.; Ye, S.; Zhang, Z. Discovery of dipeptidyl peptidase IV (DPP4) inhibitors based on a novel indole scaffold. Chin. Chem. Lett., 2014, 25(5), 673-676.
[http://dx.doi.org/10.1016/j.cclet.2014.03.047 ]
[99]
Wang, S.; Su, M.; Wang, J.; Li, Z.; Zhang, L.; Ji, X.; Li, J.; Li, J.; Liu, H. (R)-3-amino-1-((3aS,7aS)-octahydro-1H-indol-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one derivatives as potent inhibitors of dipeptidyl peptidase-4: design, synthesis, biological evaluation, and molecular modeling. Bioorg. Med. Chem., 2014, 22(23), 6684-6693.
[http://dx.doi.org/10.1016/j.bmc.2014.09.051] [PMID: 25457126]
[100]
Lübbers, T.; Böhringer, M.; Gobbi, L.; Hennig, M.; Hunziker, D.; Kuhn, B.; Löffler, B.; Mattei, P.; Narquizian, R.; Peters, J.U.; Ruff, Y.; Wessel, H.P.; Wyss, P. 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(11), 2966-2970.
[http://dx.doi.org/10.1016/j.bmcl.2007.03.072] [PMID: 17418568]
[101]
Boehringer, M.; Fischer, H.; Hennig, M.; Hunziker, D.; Huwyler, J.; Kuhn, B.; Loeffler, B.M.; Luebbers, T.; Mattei, P.; Narquizian, R.; Sebokova, E.; Sprecher, U.; Wessel, H.P. Aryl- and heteroaryl-substituted aminobenzo[a] quinolizines as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(3), 1106-1108.
[http://dx.doi.org/10.1016/j.bmcl.2009.12.025] [PMID: 20031408]
[102]
Feng, J.; Zhang, Z.; Wallace, M.B.; Stafford, J.A.; Kaldor, S.W.; Kassel, D.B.; Navre, M.; Shi, L.; Skene, R.J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D.R.; Gwaltney, S.L., 2nd Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem., 2007, 50(10), 2297-2300.
[http://dx.doi.org/10.1021/jm070104l] [PMID: 17441705]
[103]
Ali, Z.; Akhtar, M.J.; Haider, M.R.; Khan, A.A.; Siddiqui, A.A.; Yar, M.S. Design and synthesis of quinazoline-3,4-(4H)-diamine endowed with thiazoline moiety as new class for DPP-4 and DPPH inhibitor. Bioorg. Chem., 2017, 71, 181-191.
[http://dx.doi.org/10.1016/j.bioorg.2017.02.004] [PMID: 28215601]
[104]
Coppola, G.M.; Zhang, Y.L.; Schuster, H.F.; Russell, M.E.; Hughes, T.E. 1-aminomethylisoquinoline-4-carboxylates as novel dipeptidylpeptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2000, 10(14), 1555-1558.
[http://dx.doi.org/10.1016/S0960-894X(00)00286-9] [PMID: 10915049]
[105]
Banno, Y.; Miyamoto, Y.; Sasaki, M.; Oi, S.; Asakawa, T.; Kataoka, O.; Takeuchi, K.; Suzuki, N.; Ikedo, K.; Kosaka, T.; Tsubotani, S.; Tani, A.; Funami, M.; Tawada, M.; Yamamoto, Y.; Aertgeerts, K.; Yano, J.; Maezaki, H. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554. Bioorg. Med. Chem., 2011, 19(16), 4953-4970.
[http://dx.doi.org/10.1016/j.bmc.2011.06.059] [PMID: 21764322]
[106]
Sutton, J.M.; Clark, D.E.; Dunsdon, S.J.; Fenton, G.; Fillmore, A.; Harris, N.V.; Higgs, C.; Hurley, C.A.; Krintel, S.L.; MacKenzie, R.E.; Duttaroy, A.; Gangl, E.; Maniara, W.; Sedrani, R.; Namoto, K.; Ostermann, N.; Gerhartz, B.; Sirockin, F.; Trappe, J.; Hassiepen, U.; Baeschlin, D.K. Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett., 2012, 22(3), 1464-1468.
[http://dx.doi.org/10.1016/j.bmcl.2011.11.054] [PMID: 22177783]
[107]
Lin, K.; Cai, Z.; Wang, F.; Zhang, W.; Zhou, W. Synthesis and biological evaluation of xanthine derivatives on dipeptidyl peptidase 4. Chem. Pharm. Bull. (Tokyo), 2013, 61(4), 477-482.
[http://dx.doi.org/10.1248/cpb.c12-01046] [PMID: 23358258]
[108]
Mo, D.W.; Dong, S.; Sun, H.; Chen, J.S.; Pang, J.X.; Xi, B.M.; Chen, W.H. Synthesis and potent inhibitory activities of carboxybenzyl-substituted 8-(3-(R)-aminopiperidin-1-yl)-7-(2-chloro/cyanobenzyl)-3-methyl-3,7-dihydro-purine-2,6-diones as dipeptidyl peptidase IV (DPP-IV) inhibitors. Bioorg. Med. Chem. Lett., 2015, 25(9), 1872-1875.
[http://dx.doi.org/10.1016/j.bmcl.2015.03.048] [PMID: 25838146]
[109]
Li, G.; Huan, Y.; Yuan, B.; Wang, J.; Jiang, Q.; Lin, Z.; Shen, Z.; Huang, H. Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents. Eur. J. Med. Chem., 2016, 124, 103-116.
[http://dx.doi.org/10.1016/j.ejmech.2016.08.023] [PMID: 27560285]
[110]
Soni, R.; Soman, S.S. Design and synthesis of aminocoumarin derivatives as DPP-IV inhibitors and anticancer agents. Bioorg. Chem., 2018, 79, 277-284.
[http://dx.doi.org/10.1016/j.bioorg.2018.05.008] [PMID: 29783098]
[111]
Li, S.; Xu, H.; Cui, S.; Wu, F.; Zhang, Y.; Su, M.; Gong, Y.; Qiu, S.; Jiao, Q.; Qin, C.; Shan, J.; Zhang, M.; Wang, J.; Yin, Q.; Xu, M.; Liu, X.; Wang, R.; Zhu, L.; Li, J.; Xu, Y.; Jiang, H.; Zhao, Z.; Li, J.; Li, H. Discovery and rational design of natural-product-derived 2-phenyl-3, 4-dihydro-2 H-benzo [f] chromen-3-amine analogs as novel and potent dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes. J. Med. Chem., 2016, 59(14), 6772-6790.
[http://dx.doi.org/10.1021/acs.jmedchem.6b00505] [PMID: 27396490]
[112]
Abu Khalaf, R.; Jarekji, Z.; Al-Qirim, T.; Sabbah, D.; Shattat, G. Pharmacophore modeling and molecular docking studies of acridines as potential DPP-IV inhibitors. Can. J. Chem., 2015, 93(7), 721-729.
[http://dx.doi.org/10.1139/cjc-2015-0039]
[113]
Park, W.S.; Jun, M.A.; Shin, M.S.; Kwon, S.W.; Kang, S.K.; Kim, K.Y.; Dal Rhee, S.; Bae, M.A.; Narsaiah, B.; Lee, D.H.; Cheon, H.G. Synthesis and biological evaluation of triazepane derivatives as DPP-IV inhibitors. J. Fluor. Chem., 2009, 130(11), 1001-1010.
[http://dx.doi.org/10.1016/j.jfluchem.2009.08.001]
[114]
Tsai, H.J.; Chou, S.Y.; Chuang, S.H.; Chen, C.C.; Hsu, F.L. D‐420720, A novel orally active sulfonamide compound dipeptidyl peptidase IV inhibitor: structure and activity relationship of arylsulfonamide to dipeptidyl peptidase IV inhibition. Drug Dev. Res., 2008, 69(8), 514-519.
[http://dx.doi.org/10.1002/ddr.20278 ]
[115]
Sharma, R.; Soman, S.S. Design and synthesis of sulfonamide derivatives of pyrrolidine and piperidine as anti-diabetic agents. Eur. J. Med. Chem., 2015, 90, 342-350.
[http://dx.doi.org/10.1016/j.ejmech.2014.11.041] [PMID: 25437620]
[116]
Gao, H.D.; Liu, P.; Yang, Y.; Gao, F. Sulfonamide-1, 3, 5-triazine–thiazoles: discovery of a novel class of antidiabetic agents via inhibition of DPP-4. RSC Advances, 2016, 6(86), 83438-83447.
[http://dx.doi.org/10.1039/C6RA15948F]
[117]
Khalaf, R.A.; Sabbah, D.; Al-Shalabi, E.; Al-Sheikh, I.; Albadawi, G.; Abu Sheikha, G. Synthesis, structural characterization and docking studies of sulfamoyl- phenyl acid esters as dipeptidyl peptidase-iv inhibitors. Curr Comput Aided Drug Des, 2018, 14(2), 142-151.
[http://dx.doi.org/10.2174/1573409914666180308164013] [PMID: 29521244]
[118]
Abd El-Karim, S.S.; Anwar, M.M.; Syam, Y.M.; Nael, M.A.; Ali, H.F.; Motaleb, M.A. Rational design and synthesis of new tetralin-sulfonamide derivatives as potent anti-diabetics and DPP-4 inhibitors: 2D & 3D QSAR, in vivo radiolabeling and bio distribution studies. Bioorg. Chem., 2018, 81, 481-493.
[http://dx.doi.org/10.1016/j.bioorg.2018.09.021] [PMID: 30243239]
[119]
Nordhoff, S.; Cerezo-Gálvez, S.; Deppe, H.; Hill, O.; López-Canet, M.; Rummey, C.; Thiemann, M.; Matassa, V.G.; Edwards, P.J.; Feurer, A. Discovery of β-homophenylalanine based pyrrolidin-2-ylmethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett., 2009, 19(15), 4201-4203.
[http://dx.doi.org/10.1016/j.bmcl.2009.05.109] [PMID: 19515557]
[120]
Liu, Y.; Si, M.; Tang, L.; Shangguan, S.; Wu, H.; Li, J.; Wu, P.; Ma, X.; Liu, T.; Hu, Y. Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors. Bioorg. Med. Chem., 2013, 21(18), 5679-5687.
[http://dx.doi.org/10.1016/j.bmc.2013.07.034] [PMID: 23938053]
[121]
Jiang, T.; Zhou, Y.; Chen, Z.; Sun, P.; Zhu, J.; Zhang, Q.; Wang, Z.; Shao, Q.; Jiang, X.; Li, B.; Chen, K.; Jiang, H.; Wang, H.; Zhu, W.; Shen, J. Design, synthesis, and pharmacological evaluation of fused β-homophenylalanine derivatives as potent DPP-4 inhibitors. ACS Med. Chem. Lett., 2015, 6(5), 602-606.
[http://dx.doi.org/10.1021/acsmedchemlett.5b00074] [PMID: 26005541]
[122]
Boduszek, B.; Oleksyszyn, J.; Kam, C.M.; Selzler, J.; Smith, R.E.; Powers, J.C. Dipeptide phosphonates as inhibitors of dipeptidyl peptidase IV. J. Med. Chem., 1994, 37(23), 3969-3976.
[http://dx.doi.org/10.1021/jm00049a016] [PMID: 7966157]
[123]
Belyaev, A.; Zhang, X.; Augustyns, K.; Lambeir, A.M.; De Meester, I.; Vedernikova, I.; Scharpé, S.; Haemers, A. Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors. J. Med. Chem., 1999, 42(6), 1041-1052.
[http://dx.doi.org/10.1021/jm981033g] [PMID: 10090787]
[124]
Gilmore, B.F.; Carson, L.; McShane, L.L.; Quinn, D.; Coulter, W.A.; Walker, B. Synthesis, kinetic evaluation, and utilization of a biotinylated dipeptide proline diphenyl phosphonate for the disclosure of dipeptidyl peptidase IV-like serine proteases. Biochem. Biophys. Res. Commun., 2006, 347(1), 373-379.
[http://dx.doi.org/10.1016/j.bbrc.2006.06.113] [PMID: 16824486]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy